Internal Medicine, Endocrinology, Diabetes, & Metabolism · Harlingen, TX
NPI
1043659345
Since 2013
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
620 N ED Carey Dr
Harlingen, TX, 78550
Phone (956) 230-4971
Groups this clinician bills Medicare through
Medicare paid, 2024
$68K
1,462 services
Medicare patients, 2024
241
Average age 68
Drug cost, 2024
$6.0M
7,582 prescriptions
Company payments, 2025
$420
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Syed A Hassan was code 99214 (office e&m - established), 356 times for 166 patients. In total Syed A Hassan billed 1,462 services in 17 codes, and Medicare paid $68K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-07-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 356 | 166 | $87.01 | $31K |
| 99422 Office/Outpatient Services | Office | 354 | 16 | $22.25 | $7,875 |
| 82962 Clinical Chemistry | Office | 204 | 109 | $3.21 | $655 |
| 95251 Test - Miscellaneous | Office | 199 | 47 | $24.90 | $4,955 |
| 83036 Blood Count | Office | 138 | 89 | $9.52 | $1,314 |
| 99204 Office E&M - New | Office | 54 | 54 | $124.75 | $6,737 |
| 99213 Office E&M - Established | Office | 37 | 28 | $68.12 | $2,521 |
| 76536 Ultrasound - Nonspecific | Office | 23 | 21 | $80.15 | $1,843 |
| 99203 Office E&M - New | Office | 17 | 17 | $73.66 | $1,252 |
| 99223 Hospital E&M - Initial | Facility | 13 | 13 | $131.55 | $1,710 |
By year: 2022 $82K for 1,422 services; 2023 $71K for 1,349 services; 2024 $68K for 1,462 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 204 | 109 | $3.21 | $655 |
| 83036 Blood Count | 138 | 89 | $9.52 | $1,314 |
Medicare prescription drug claims, 2024
In 2024, the drug Syed A Hassan prescribed most often to Medicare patients was Ozempic (Semaglutide), with 1,506 prescriptions and refills. In total Syed A Hassan wrote 7,582 Medicare prescriptions that cost $6.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 1,506 | 2,489 | 380 | $2.4M |
| Mounjaro Tirzepatide | 601 | 941 | 162 | $992K |
| Jardiance Empagliflozin | 456 | 1,003 | 140 | $553K |
| Levothyroxine Sodium Generic | 363 | 951 | 108 | $4,440 |
| Pioglitazone Hcl Generic | 344 | 912 | 130 | $5,048 |
| Tresiba Flextouch U-100 Insulin Degludec | 316 | 832 | 115 | $280K |
| Metformin Hcl Generic | 213 | 596 | 82 | $1,702 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 202 | 564 | 99 | $27K |
| Trulicity Dulaglutide | 166 | 290 | 45 | $280K |
| Farxiga Dapagliflozin Propanediol | 148 | 262 | 42 | $142K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 127 | 322 | 55 | $22K |
| Novolog Flexpen Insulin Aspart | 112 | 253 | 42 | $33K |
| Alendronate Sodium Generic | 110 | 269 | 37 | $727 |
| Humalog Kwikpen U-100 Insulin Lispro | 104 | 258 | 47 | $35K |
| Insulin Lispro Kwikpen U-100 Insulin Lispro | 101 | 233 | 45 | $35K |
Brand drugs: 4,644 claims; generic drugs: 2,335 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Syed A Hassan $420 ($420 in general payments such as food, travel and fees) from 9 companies. The largest payer was Abbott Laboratories with $221.
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories ABT | 11 | $221 |
| Recordati_rare_diseases_inc. | 2 | $44.43 |
| Tandem Diabetes Care, Inc. TNDM | 1 | $40.22 |
| Madrigal Pharmaceuticals MDGL | 1 | $36.62 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $22.13 |
| Dexcom, Inc. DXCM | 1 | $17.65 |
| Lilly USA, LLC LLY | 1 | $15.53 |
| Antares Pharma, Inc. | 1 | $15.11 |
| CeQur Corporation | 1 | $7.8 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.